TP53 and cancer: Of note, 43% of CRCs harbor p53 mutations (IARC TP53 database, R20; https://p53.iarc.fr/tp53SomaticMutations.aspx), of which approximately 90% mutations are missense mutations that impair wild-type p53 function (loss-of-function mutations) and might endow neo-morphic (gain-of-function mutations) to promote cancer progression 4.